AF
ARQT icon

Allworth Financial’s Arcutis Biotherapeutics ARQT Stock Holding History

Allworth Financial’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.2K Sell
809
-20
-2% -$466 ﹤0.01% 3149
2026
Q1 		$19.5K Buy
829
+102
+14% +$2.6K ﹤0.01% 3019
2025
Q4 		$21.1K Buy
727
+141
+24% +$3.61K ﹤0.01% 2782
2025
Q3 		$11K Buy
586
+563
+2,448% +$8.88K ﹤0.01% 3081
2025
Q2 		$323 Buy
+23
New +$322 ﹤0.01% 4232
2023
Q4 		– Sell
-59
Closed -$314 – 3467
2023
Q3 		$314 Buy
59
+18
+44% +$153 ﹤0.01% 3157
2023
Q2 		$391 Buy
+41
New +$455 ﹤0.01% 2941

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Allworth Financial's ARQT Position: Q2 2026 in Review

Allworth Financial reduced its Arcutis Biotherapeutics (ARQT) stake by 2.4% in Q2 2026, selling an estimated $466 and leaving 809 shares worth $21.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3149.

Allworth Financial first reported a position in ARQT in Q2 2023 and has held it in 7 quarters since. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Allworth Financial held 809 shares of Arcutis Biotherapeutics worth $21.2K as of Q2 2026.
  • Allworth Financial sold 20 Arcutis Biotherapeutics shares in Q2 2026, an estimated $466.
  • Arcutis Biotherapeutics made up ﹤0.01% of Allworth Financial's portfolio in Q2 2026, its #3149 holding.
  • Allworth Financial first reported a position in Arcutis Biotherapeutics in Q2 2023 and has held it in 7 quarters since.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Allworth Financial's 13F filing for Q2 2026, filed 11 Aug 2026.